AU2003286546B2 - Method to treat chronic heart failure and/or elevated cholesterol levels - Google Patents

Method to treat chronic heart failure and/or elevated cholesterol levels Download PDF

Info

Publication number
AU2003286546B2
AU2003286546B2 AU2003286546A AU2003286546A AU2003286546B2 AU 2003286546 B2 AU2003286546 B2 AU 2003286546B2 AU 2003286546 A AU2003286546 A AU 2003286546A AU 2003286546 A AU2003286546 A AU 2003286546A AU 2003286546 B2 AU2003286546 B2 AU 2003286546B2
Authority
AU
Australia
Prior art keywords
acid
administered
triiodothyropropionic
tetraiodothyropropionic
triprop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003286546A
Other languages
English (en)
Other versions
AU2003286546A1 (en
Inventor
Eugene Morkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arizona's Public Universities
Original Assignee
University of Arizona
Arizona's Public Universities
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Arizona, Arizona's Public Universities filed Critical University of Arizona
Publication of AU2003286546A1 publication Critical patent/AU2003286546A1/en
Application granted granted Critical
Publication of AU2003286546B2 publication Critical patent/AU2003286546B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2003286546A 2003-02-18 2003-10-20 Method to treat chronic heart failure and/or elevated cholesterol levels Ceased AU2003286546B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/368,755 2003-02-18
US10/368,755 US6716877B2 (en) 2001-01-31 2003-02-18 Method to treat chronic heart failure and/or elevated cholesterol levels
PCT/US2003/033333 WO2004073694A1 (en) 2003-02-18 2003-10-20 Method to treat chronic heart failure and/or elevated cholesterol levels

Publications (2)

Publication Number Publication Date
AU2003286546A1 AU2003286546A1 (en) 2004-09-09
AU2003286546B2 true AU2003286546B2 (en) 2009-06-11

Family

ID=32907645

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003286546A Ceased AU2003286546B2 (en) 2003-02-18 2003-10-20 Method to treat chronic heart failure and/or elevated cholesterol levels

Country Status (7)

Country Link
US (1) US6716877B2 (https=)
EP (1) EP1594480A4 (https=)
JP (1) JP2006514665A (https=)
AU (1) AU2003286546B2 (https=)
CA (1) CA2516450A1 (https=)
MX (1) MXPA05008596A (https=)
WO (1) WO2004073694A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI107018B (fi) * 2000-04-06 2001-05-31 Ipsat Therapies Oy Dermatologinen käyttö ja valmiste
US7504435B2 (en) * 2001-01-31 2009-03-17 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for stimulating weight loss and/or for lowering triglycerides in patients
WO2006128058A2 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
CN1882327A (zh) * 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
WO2006128056A2 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
EP2199271A4 (en) * 2007-08-31 2011-05-18 Mitsubishi Gas Chemical Co METHOD FOR PRODUCING PHENOL DERIVATIVES SUBSTITUTED WITH IODINE AT THE ORTHO POSITION
US20090131380A1 (en) * 2007-11-16 2009-05-21 Pekka Heino Novel pharmaceutical composition for topical treatment of skin psoriasis and the treatment method thereof
MX386702B (es) * 2014-02-10 2025-03-19 Fred Hutchinson Cancer Center Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
CA3044059A1 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
US11458094B2 (en) * 2018-01-31 2022-10-04 Regents Of The University Of Minnesota Compositions and methods for treating pulmonary edema or lung inflammation
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
CA3177377A1 (en) 2020-03-27 2021-09-30 Regents Of The University Of Minnesota Compositions and methods for treating pulmonary edema or lung inflammation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221911B1 (en) * 1995-06-07 2001-04-24 Karo Bio Ab Uses for thyroid hormone compounds or thyroid hormone-like compounds
WO2002060389A2 (en) * 2001-01-31 2002-08-08 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3109023A (en) 1958-06-10 1963-10-29 Hooker Chemical Corp 2, 3, 6-trichloro-5-nitrobenzoic acid and salts thereof
US5158978A (en) * 1990-02-05 1992-10-27 British Technology Group (U.S.A.) Thyroid hormone treatment of acute cardiovascular compromise
US5284971A (en) 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221911B1 (en) * 1995-06-07 2001-04-24 Karo Bio Ab Uses for thyroid hormone compounds or thyroid hormone-like compounds
WO2002060389A2 (en) * 2001-01-31 2002-08-08 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bauer, HG. et al, 1959:19(4):490-93 *
Morkin, E. et al, 2002. Cardiology. 97:218-225 *

Also Published As

Publication number Publication date
WO2004073694A1 (en) 2004-09-02
EP1594480A1 (en) 2005-11-16
US6716877B2 (en) 2004-04-06
CA2516450A1 (en) 2004-09-02
EP1594480A4 (en) 2007-08-29
JP2006514665A (ja) 2006-05-11
AU2003286546A1 (en) 2004-09-09
US20030147815A1 (en) 2003-08-07
MXPA05008596A (es) 2006-02-28

Similar Documents

Publication Publication Date Title
US6534676B2 (en) Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
AU2002243801A1 (en) Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
AU2003286546B2 (en) Method to treat chronic heart failure and/or elevated cholesterol levels
US6045827A (en) Treatment of equine laminitis
KR100267442B1 (ko) 아세틸살리실산을 함유하는 혈전증 치료용 및 암 예방용 경피적 투여시스템
Yau et al. Vitamin E for coronary bypass operations: a prospective, double-blind, randomized trial
US8071125B2 (en) Transdermal patch containing isosorbide dinitrate and bisoprolol
JP2001515864A (ja) 非天然ｆｐ選択的作用薬を使用した骨体積増加方法
CN118001256A (zh) 氟比洛芬的外用制剂及其制备方法
JP2540294B2 (ja) 経皮吸収製剤
US20050159490A1 (en) Method to treat chronic heart failure and/or elevated cholesterol levels
US20050266060A1 (en) Transdermal delivery system for treatment of cognitive disorders
AU2001287706B2 (en) Treatment of burns
SK75495A3 (en) Transdermal administration system containing acetylsalicylic acid for antithrombotic therapy and the prophylaxis of cancer
BE1018506A3 (nl) Samenstelling van een hydrocortisone, zijn derivaten, metabolieten, prodrugs of mengsels daarvan houdende liposomale gel en het gebruik ervan.
AU2001287706A1 (en) Treatment of burns
CN114469878A (zh) 一种普罗布考干乳剂组合物及其制备方法和应用
JPH0193542A (ja) 医薬外用製剤
JPS62106013A (ja) 外用投与用組成物
JPH06247846A (ja) 塩酸リトドリンの経皮吸収製剤用組成物
JPS63218630A (ja) 経皮吸収促進剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired